Slawomir Lukomski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Slawomir Lukomski has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
Soo Jeon Choi
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA
10 shared publicationsClayton C. Caswell
Department of Microbiology, Immunology, and Cell Biology, West Virginia University Morgantown, WV, USA
9 shared publicationsRita Berisio
Institute of Biostructure and Bioimaging National Research Council, CNR Naples Italy
9 shared publicationsDouglas R. Keene
The Micro-imaging Center, Shriners Hospital for Children, Portland, Oregon 97239
6 shared publicationsEwa Lukomska
Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV, USA
6 shared publicationsP. Rocco LaSala
Department of Pathology, West Virginia University School of Medicine, Morgantown, WV, USA
6 shared publications
Latest Publications
- Open Access
- 30 May 2026
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 4 (1)
Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus
A multi-drug resistant emm92-type strain of group A Streptococcus (GAS) has emerged as an important causative agent of invasive infections-particularly affecting people who inject drugs-in the United States. To curtail this developing threat, we aimed to identify and repurpose FDA-investigated compounds as antimicrobials. To identify growth-inhibiting compounds, a machine learning-based model was trained on the emm92-iGAS growth response to 2560 bioactive compounds. The model was used to screen a 6111 FDA-evaluated drug library in silico. Of the 9 validated compounds, GW3965 experimentally exhibited a 99% reduction in iGAS survival at an MIC of 6.25 µM. Treatment with GW3965 aided complete wound closure in a human skin equivalent model, and decreased lesion size and reduced bacterial burden in a mouse model of skin and soft tissue infection. Application of a machine learning model expedited the discovery of GW3965 as a therapeutic for iGAS skin and soft tissue infections.
- 30 May 2026
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 4 (1)
Open AccessMachine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus
A multi-drug resistant emm92-type strain of group A Streptococcus (GAS) has emerged as an important causative agent of invasive infections-particularly affecting people who inject drugs-in the United States. To curtail this developing threat, we aimed to identify and repurpose FDA-investigated compounds as antimicrobials. To identify growth-inhibiting compounds, a machine learning-based model was trained on the emm92-iGAS growth response to 2560 bioactive compounds. The model was used to screen a 6111 FDA-evaluated drug library in silico. Of the 9 validated compounds, GW3965 experimentally exhibited a 99% reduction in iGAS survival at an MIC of 6.25 µM. Treatment with GW3965 aided complete wound closure in a human skin equivalent model, and decreased lesion size and reduced bacterial burden in a mouse model of skin and soft tissue infection. Application of a machine learning model expedited the discovery of GW3965 as a therapeutic for iGAS skin and soft tissue infections.
- Open Access
- 15 May 2026
- Published by Wiley in Molecular Microbiology
- Vol. 126 (1) , 47-59
The Complexity of erm ‐Mediated Resistance: Structural and Functional Perspectives From β‐Hemolytic Streptococci
Macrolide overuse and resulting resistance crippled the applicability of one of the most important and successful classes of antibiotics. The rising incidence of invasive infections caused by β‐hemolytic group A and group B streptococci have been paralleled with marked increases in erythromycin and clindamycin resistance. As a result, resistant invasive group A and group B Streptococcus infections have been classified by the CDC as a concerning level threat since 2019. Acquisition of erythromycin resistance methylase ( erm ) genes is a major contributor of the MLS B [macrolide (i.e., erythromycin), lincosamide (i.e., clindamycin), and streptogramin B] resistance phenotype in US isolates. The erm ‐encoded enzymes utilize the methyl‐group from S‐adenosyl‐L‐methionine (SAM) to methylate the adenosine A2058 residue of bacterial ribosomal RNA, which serves as the overlapping rRNA target site for the three MLS B classes of antibiotics. The major mechanism that regulates Erm methyltransferase production is translational attenuation in the 5′ regulatory region upstream of the erm coding sequence. The 5′ regulatory region of erm includes at least one short leader peptide erm L, with the leader peptide ribosome binding site (SD1), non‐translational stem‐loop structures, and the erm start codon with its ribosome binding site (SD2). Binding of a macrolide antibiotic to the ribosome causes stalling during translation of the erm L peptide, which disrupts and alters the formation of inhibitory mRNA hairpins in the erm 5′ regulatory region, thereby releasing the erm SD2‐site from the posterior stem‐loop hairpin, thus allowing Erm protein translation. The streptococcal ErmA, ErmB, and ErmT proteins have conserved structures with primary sequence conservation of residues involved in SAM‐ and rRNA‐binding activity, as well as a high‐level of structural conservation. However, the observed variation in the erm 5′ regulatory region sequences, transcript expression, and ribosome methylation levels associated with these genes and proteins underscore the regulatory complexity of Erm expression. This review aims to present insights into mechanisms of Erm‐mediated resistance, trends in streptococcal epidemiology and treatment, and progress in the development of improved MLS B drugs that effectively block erm ‐mediated resistance.
- 15 May 2026
- Published by Wiley in Molecular Microbiology
- Vol. 126 (1) , 47-59
Open AccessThe Complexity of erm ‐Mediated Resistance: Structural and Functional Perspectives From β‐Hemolytic Streptococci
Macrolide overuse and resulting resistance crippled the applicability of one of the most important and successful classes of antibiotics. The rising incidence of invasive infections caused by β‐hemolytic group A and group B streptococci have been paralleled with marked increases in erythromycin and clindamycin resistance. As a result, resistant invasive group A and group B Streptococcus infections have been classified by the CDC as a concerning level threat since 2019. Acquisition of erythromycin resistance methylase ( erm ) genes is a major contributor of the MLS B [macrolide (i.e., erythromycin), lincosamide (i.e., clindamycin), and streptogramin B] resistance phenotype in US isolates. The erm ‐encoded enzymes utilize the methyl‐group from S‐adenosyl‐L‐methionine (SAM) to methylate the adenosine A2058 residue of bacterial ribosomal RNA, which serves as the overlapping rRNA target site for the three MLS B classes of antibiotics. The major mechanism that regulates Erm methyltransferase production is translational attenuation in the 5′ regulatory region upstream of the erm coding sequence. The 5′ regulatory region of erm includes at least one short leader peptide erm L, with the leader peptide ribosome binding site (SD1), non‐translational stem‐loop structures, and the erm start codon with its ribosome binding site (SD2). Binding of a macrolide antibiotic to the ribosome causes stalling during translation of the erm L peptide, which disrupts and alters the formation of inhibitory mRNA hairpins in the erm 5′ regulatory region, thereby releasing the erm SD2‐site from the posterior stem‐loop hairpin, thus allowing Erm protein translation. The streptococcal ErmA, ErmB, and ErmT proteins have conserved structures with primary sequence conservation of residues involved in SAM‐ and rRNA‐binding activity, as well as a high‐level of structural conservation. However, the observed variation in the erm 5′ regulatory region sequences, transcript expression, and ribosome methylation levels associated with these genes and proteins underscore the regulatory complexity of Erm expression. This review aims to present insights into mechanisms of Erm‐mediated resistance, trends in streptococcal epidemiology and treatment, and progress in the development of improved MLS B drugs that effectively block erm ‐mediated resistance.
- Open Access
- 21 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Application of group A streptococcal collagen-like protein 1-expressing Lactococcus as a novel immunotherapeutic against pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy characterized by an immunosuppressive tumor environment. Neutrophil extracellular traps (NETs) have gained recognition in playing a critical role in cancer progression and formulation of the PDAC TME, making them a target for novel PDAC therapies. Herein, we utilize a Lactococcus strain expressing group A streptococcal collagen-like protein 1 (Scl1) to stimulate anti-tumor immunity and inhibit cancer promoting NETs. Orthotopically implanted male and female C57BL6/J or NET-deficient PAD4−/− mice were intra-tumorally or intra-peritoneally injected with Lactococcus wild-type lacking Scl1, Scl1-producing Lactococcus::620, or PBS control. Sera were collected to assess circulating NET markers. A decreased tumor burden, as well as infiltration of anti-tumor CD8 + T and dendritic cells was observed in mice treated with Scl1-expressing Lactococcus::620 compared to Lactococcus wild-type and PBS control. Mice treated with Lactococcus::620 showed reduced cell-free DNA in their sera as a marker for decreased NETosis. These effects were abrogated in PAD4−/− mice, suggesting a NET-dependent anti-tumor effect by Scl1. This study demonstrates a novel therapeutic concept against PDAC using an engineered Scl1-expressing Lactococcus strain. Our results advocate for Scl1-based cancer therapy as an immunomodulator of the PDAC tumor microenvironment.
- 21 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessApplication of group A streptococcal collagen-like protein 1-expressing Lactococcus as a novel immunotherapeutic against pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy characterized by an immunosuppressive tumor environment. Neutrophil extracellular traps (NETs) have gained recognition in playing a critical role in cancer progression and formulation of the PDAC TME, making them a target for novel PDAC therapies. Herein, we utilize a Lactococcus strain expressing group A streptococcal collagen-like protein 1 (Scl1) to stimulate anti-tumor immunity and inhibit cancer promoting NETs. Orthotopically implanted male and female C57BL6/J or NET-deficient PAD4−/− mice were intra-tumorally or intra-peritoneally injected with Lactococcus wild-type lacking Scl1, Scl1-producing Lactococcus::620, or PBS control. Sera were collected to assess circulating NET markers. A decreased tumor burden, as well as infiltration of anti-tumor CD8 + T and dendritic cells was observed in mice treated with Scl1-expressing Lactococcus::620 compared to Lactococcus wild-type and PBS control. Mice treated with Lactococcus::620 showed reduced cell-free DNA in their sera as a marker for decreased NETosis. These effects were abrogated in PAD4−/− mice, suggesting a NET-dependent anti-tumor effect by Scl1. This study demonstrates a novel therapeutic concept against PDAC using an engineered Scl1-expressing Lactococcus strain. Our results advocate for Scl1-based cancer therapy as an immunomodulator of the PDAC tumor microenvironment.
- Open Access
- 11 December 2025
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 14 (12) , e0084025
Transcriptome of macrolide-resistant emm92 invasive group A Streptococcus in response to erythromycin exposure
Macrolide-resistant emm92 -type invasive Streptococcus pyogenes has emerged in the United States since 2010, posing the question of whether acquired erm (T)-encoded resistance may have contributed to the rise in infections. Here, we present the transcriptomes for two Streptococcus pyogenes isolates of emm -type 92 in response to erythromycin exposure.
- 11 December 2025
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 14 (12) , e0084025
Open AccessTranscriptome of macrolide-resistant emm92 invasive group A Streptococcus in response to erythromycin exposure
Macrolide-resistant emm92 -type invasive Streptococcus pyogenes has emerged in the United States since 2010, posing the question of whether acquired erm (T)-encoded resistance may have contributed to the rise in infections. Here, we present the transcriptomes for two Streptococcus pyogenes isolates of emm -type 92 in response to erythromycin exposure.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1686688
Structural and genomic insights into erythromycin and clindamycin resistance of group B Streptococcus isolates in rural West Virginia, United States
Introduction: Group B Streptococcus (GBS) is a leading etiological agent of neonatal sepsis and meningitis, as well as invasive infections that predominately affect adults over 65 and people with comorbidities. The Centers for Disease Control and Prevention’s (CDC) nationwide surveillance has identified rising clindamycin and erythromycin resistance as a concerning level threat for invasive GBS infections. West Virginia (WV) is a rural state outside the CDC catchment area, therefore, we investigated 65 WV-GBS isolates identified in clinical specimens from various sources for serotype distribution, as well as the spectrum and genetic markers of erythromycin and clindamycin resistance. Results: GBS isolates of serotypes II (27.7%), Ib (23.1%), V (18.5%), Ia (13.8%), III (10.8%), and IV (6.2%), were identified. The mef (A) gene encoding macrolide resistance (M phenotype) was detected in 15.4% isolates. The erm (A) and erm (B) genes that are responsible for the combined erythromycin and clindamycin resistance, which characterizes an MLS B [macrolide, lincosamide, and streptogramin B] resistance phenotype, were detected in 67.7% of WV-GBS isolates; also, 81.4% of those displayed constitutive (cMLS B ) and 18.6% inducible (iMLS B ) resistance to clindamycin by erythromycin using the D-test. A cluster of mutations within the regulatory region of erm (A) were identified in association with a cMLS B sub-phenotype, whereas most of the erm (B) promoters sequenced from isolates with a cMLS B background lacked analogous sequence polymorphisms. Further, higher erythromycin MIC values were associated with the erm (B) determinant compared with erm (A), while structural models of the GBS-ErmA and GBS-ErmB enzymes show conservation in both SAM- and rRNA-binding sites. Significance: Our data demonstrate that the 80.0% rate of erythromycin and 70.8% of clindamycin resistance in WV is higher than the national average of 61.7 and 52.5%, respectively, while being widespread across a variety of clinical specimens (urine, throat, respiratory tract, blood, foot ulcers, perisplenic fluid, various wounds, and the rectovaginal area). Providers should be aware of the current threat of antibiotic resistance, especially in “primary care deserts” existing in rural areas such as WV.
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1686688
Open AccessStructural and genomic insights into erythromycin and clindamycin resistance of group B Streptococcus isolates in rural West Virginia, United States
Introduction: Group B Streptococcus (GBS) is a leading etiological agent of neonatal sepsis and meningitis, as well as invasive infections that predominately affect adults over 65 and people with comorbidities. The Centers for Disease Control and Prevention’s (CDC) nationwide surveillance has identified rising clindamycin and erythromycin resistance as a concerning level threat for invasive GBS infections. West Virginia (WV) is a rural state outside the CDC catchment area, therefore, we investigated 65 WV-GBS isolates identified in clinical specimens from various sources for serotype distribution, as well as the spectrum and genetic markers of erythromycin and clindamycin resistance. Results: GBS isolates of serotypes II (27.7%), Ib (23.1%), V (18.5%), Ia (13.8%), III (10.8%), and IV (6.2%), were identified. The mef (A) gene encoding macrolide resistance (M phenotype) was detected in 15.4% isolates. The erm (A) and erm (B) genes that are responsible for the combined erythromycin and clindamycin resistance, which characterizes an MLS B [macrolide, lincosamide, and streptogramin B] resistance phenotype, were detected in 67.7% of WV-GBS isolates; also, 81.4% of those displayed constitutive (cMLS B ) and 18.6% inducible (iMLS B ) resistance to clindamycin by erythromycin using the D-test. A cluster of mutations within the regulatory region of erm (A) were identified in association with a cMLS B sub-phenotype, whereas most of the erm (B) promoters sequenced from isolates with a cMLS B background lacked analogous sequence polymorphisms. Further, higher erythromycin MIC values were associated with the erm (B) determinant compared with erm (A), while structural models of the GBS-ErmA and GBS-ErmB enzymes show conservation in both SAM- and rRNA-binding sites. Significance: Our data demonstrate that the 80.0% rate of erythromycin and 70.8% of clindamycin resistance in WV is higher than the national average of 61.7 and 52.5%, respectively, while being widespread across a variety of clinical specimens (urine, throat, respiratory tract, blood, foot ulcers, perisplenic fluid, various wounds, and the rectovaginal area). Providers should be aware of the current threat of antibiotic resistance, especially in “primary care deserts” existing in rural areas such as WV.
- Open Access
- 31 January 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (1) , e0033024
Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection
The incidence of infections attributed to antimicrobial-resistant (AMR) pathogens has increased exponentially over the recent decades reaching 1.27 million deaths worldwide in 2019. Without intervention, these infections are predicted to cause up to 10 million deaths a year and incur costs of up to 100 trillion US dollars globally by 2050. The emergence of AMR bacteria such as the ESKAPEE pathogens, and in particular Pseudomonas aeruginosa and species from the genus Burkholderia , underscores an urgent need for new therapeutic strategies. Monoclonal antibody (mAb) therapy offers a promising alternative to treat and prevent bacterial infections. In this study, we used peptides from highly conserved areas of the bacterial flagellin to generate monoclonal antibodies capable of broad binding to flagellated Gram-negative bacteria. We generated a broadly reactive IgG2bĸ mAb (WVDC-2109) that recognizes P. aeruginosa, Burkholderia sp., and other Gram-negative pathogens of interest. Characterization of the therapeutic potential of this antibody was determined using P. aeruginosa as model. In vitro characterization of WVDC-2109 demonstrated complement-mediated bactericidal activity and enhanced opsonophagocytosis of P. aeruginosa . Prophylactic administration of WVDC-2109 markedly improved survival and outcome in a lethal sepsis model and a sub-lethal murine pneumonia model of P. aeruginosa infection, reducing bacterial burden and inflammation. These findings suggest that WVDC-2109 and similar FliC-targeting antibodies could be valuable in preventing or treating diseases caused by P. aeruginosa as well as other life-threatening diseases of concern. IMPORTANCE: Antimicrobial resistance (AMR) costs hundreds of thousands of lives and billions of dollars annually. To protect the population against these infections, it is imperative to develop new medical countermeasures targeting AMR pathogens like P. aeruginosa and Burkholderia sp. The administration of broadly reactive monoclonal antibodies can represent an alternative to treat and prevent infections caused by multi-drug-resistant bacteria. Unlike vaccines, antibodies can provide protection regardless of the immune status of the infected host. In this study, we generated an antibody capable of recognizing flagellin from P. aeruginosa and B. pseudomallei along with other Gram-negative pathogens of concern. Our findings demonstrate that the administration of the monoclonal antibody WVDC-2109 enhances survival rates and outcomes in different murine models of P. aeruginosa infection. These results carry significant implications in the field given that there are no available vaccines for P. aeruginosa .
- 31 January 2025
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 93 (1) , e0033024
Open AccessNovel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection
The incidence of infections attributed to antimicrobial-resistant (AMR) pathogens has increased exponentially over the recent decades reaching 1.27 million deaths worldwide in 2019. Without intervention, these infections are predicted to cause up to 10 million deaths a year and incur costs of up to 100 trillion US dollars globally by 2050. The emergence of AMR bacteria such as the ESKAPEE pathogens, and in particular Pseudomonas aeruginosa and species from the genus Burkholderia , underscores an urgent need for new therapeutic strategies. Monoclonal antibody (mAb) therapy offers a promising alternative to treat and prevent bacterial infections. In this study, we used peptides from highly conserved areas of the bacterial flagellin to generate monoclonal antibodies capable of broad binding to flagellated Gram-negative bacteria. We generated a broadly reactive IgG2bĸ mAb (WVDC-2109) that recognizes P. aeruginosa, Burkholderia sp., and other Gram-negative pathogens of interest. Characterization of the therapeutic potential of this antibody was determined using P. aeruginosa as model. In vitro characterization of WVDC-2109 demonstrated complement-mediated bactericidal activity and enhanced opsonophagocytosis of P. aeruginosa . Prophylactic administration of WVDC-2109 markedly improved survival and outcome in a lethal sepsis model and a sub-lethal murine pneumonia model of P. aeruginosa infection, reducing bacterial burden and inflammation. These findings suggest that WVDC-2109 and similar FliC-targeting antibodies could be valuable in preventing or treating diseases caused by P. aeruginosa as well as other life-threatening diseases of concern. IMPORTANCE: Antimicrobial resistance (AMR) costs hundreds of thousands of lives and billions of dollars annually. To protect the population against these infections, it is imperative to develop new medical countermeasures targeting AMR pathogens like P. aeruginosa and Burkholderia sp. The administration of broadly reactive monoclonal antibodies can represent an alternative to treat and prevent infections caused by multi-drug-resistant bacteria. Unlike vaccines, antibodies can provide protection regardless of the immune status of the infected host. In this study, we generated an antibody capable of recognizing flagellin from P. aeruginosa and B. pseudomallei along with other Gram-negative pathogens of concern. Our findings demonstrate that the administration of the monoclonal antibody WVDC-2109 enhances survival rates and outcomes in different murine models of P. aeruginosa infection. These results carry significant implications in the field given that there are no available vaccines for P. aeruginosa .
- Open Access
- 26 December 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (1) , dlaf021
Insights into MLSB resistance in invasive group A streptococci in West Virginia, USA
- 26 December 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (1) , dlaf021
Open AccessInsights into MLSB resistance in invasive group A streptococci in West Virginia, USA
- Open Access
- 29 November 2024
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 2 (1) , 1-13
Regulation of erm(T) MLSB phenotype expression in the emergent emm92 type group A Streptococcus
In the last decade, invasive group A Streptococcus (iGAS) infections have doubled in the US, with equivalent increases in MLSB (macrolide, lincosamide, and streptogramin B)-resistance. The emm92-type isolates carrying the erm(T) gene have been associated with an alarming emergence of iGAS infections in people who inject drugs or experience homelessness. Our goal was to elucidate the mechanisms behind inducible (iMLSB) and constitutive (cMLSB) resistance in emm92 isolates. Sequence analysis identified polymorphisms in the erm(T) regulatory region associated with cMLSB resistance. RT-qPCR and RNAseq revealed increased erm(T) mRNA levels in iMLSB isolates in response to erythromycin exposure, while cMLSB isolates exhibited high erm(T) expression independent from antibiotic exposure. Transcription results were coupled with shifting levels of ribosomal methylation. A homology model of the ErmT enzyme identified structural elements and residues conserved in methyltransferases. Delayed growth of iMLSB isolates cultured with erythromycin and increased clindamycin resistance in cMLSB isolates were observed.
- 29 November 2024
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 2 (1) , 1-13
Open AccessRegulation of erm(T) MLSB phenotype expression in the emergent emm92 type group A Streptococcus
In the last decade, invasive group A Streptococcus (iGAS) infections have doubled in the US, with equivalent increases in MLSB (macrolide, lincosamide, and streptogramin B)-resistance. The emm92-type isolates carrying the erm(T) gene have been associated with an alarming emergence of iGAS infections in people who inject drugs or experience homelessness. Our goal was to elucidate the mechanisms behind inducible (iMLSB) and constitutive (cMLSB) resistance in emm92 isolates. Sequence analysis identified polymorphisms in the erm(T) regulatory region associated with cMLSB resistance. RT-qPCR and RNAseq revealed increased erm(T) mRNA levels in iMLSB isolates in response to erythromycin exposure, while cMLSB isolates exhibited high erm(T) expression independent from antibiotic exposure. Transcription results were coupled with shifting levels of ribosomal methylation. A homology model of the ErmT enzyme identified structural elements and residues conserved in methyltransferases. Delayed growth of iMLSB isolates cultured with erythromycin and increased clindamycin resistance in cMLSB isolates were observed.
- Open Access
- 4 October 2024
- Published by Springer Nature in Research Square
Translation-transcription coupled regulation of erm(T) MLSB sub-phenotype expression in the emergent emm92-type group A Streptococcus
In the last decade, invasive group A Streptococcus (iGAS) infections have doubled in the U.S., with equivalent increases in MLSB (macrolide, lincosamide, and streptogramin B)-resistance. The emm92-type isolates carrying the erm(T) gene have been associated with an alarming emergence of iGAS infections in people who inject drugs or experiencing homelessness. Our goal was to elucidate the mechanisms behind inducible (iMLSB) and constitutive (cMLSB) resistance in emm92 isolates. Sequence analysis identified polymorphisms in the erm(T) regulatory region associated with cMLSB resistance. RT-qPCR and RNAseq revealed increased erm(T) mRNA levels in iMLSB isolates in response to erythromycin exposure, while cMLSB isolates exhibited high erm(T) expression independent from antibiotic exposure. Transcription results were coupled with shifting levels of ribosomal methylation. A homology model of the ErmT enzyme identified structural elements and residues conserved in methyltransferases. Delayed growth of iMLSB isolates cultured with erythromycin and increased clindamycin resistance in cMLSB isolates were observed.
- 4 October 2024
- Published by Springer Nature in Research Square
Open AccessTranslation-transcription coupled regulation of erm(T) MLSB sub-phenotype expression in the emergent emm92-type group A Streptococcus
In the last decade, invasive group A Streptococcus (iGAS) infections have doubled in the U.S., with equivalent increases in MLSB (macrolide, lincosamide, and streptogramin B)-resistance. The emm92-type isolates carrying the erm(T) gene have been associated with an alarming emergence of iGAS infections in people who inject drugs or experiencing homelessness. Our goal was to elucidate the mechanisms behind inducible (iMLSB) and constitutive (cMLSB) resistance in emm92 isolates. Sequence analysis identified polymorphisms in the erm(T) regulatory region associated with cMLSB resistance. RT-qPCR and RNAseq revealed increased erm(T) mRNA levels in iMLSB isolates in response to erythromycin exposure, while cMLSB isolates exhibited high erm(T) expression independent from antibiotic exposure. Transcription results were coupled with shifting levels of ribosomal methylation. A homology model of the ErmT enzyme identified structural elements and residues conserved in methyltransferases. Delayed growth of iMLSB isolates cultured with erythromycin and increased clindamycin resistance in cMLSB isolates were observed.
- Open Access
- 7 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1363962
Group A streptococcal collagen-like protein 1 restricts tumor growth in murine pancreatic adenocarcinoma and inhibits cancer-promoting neutrophil extracellular traps
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer associated with an immunosuppressive environment. Neutrophil extracellular traps (NETs) were initially described in the context of infection but have more recently been implicated in contributing to the tolerogenic immune response in PDAC. Thus, NETs are an attractive target for new therapeutic strategies. Group A Streptococcus (GAS) has developed defensive strategies to inhibit NETs.Methods: In the present work, we propose utilizing intra-tumoral GAS injection to stimulate anti-tumor activity by inhibiting cancer-promoting NETs. Mice harboring Panc02 or KPC subcutaneous tumors injected with three different M-type GAS strains. Tumors and spleens were harvested at the endpoint of the experiments to assess bacterial colonization and systemic spread, while sera were analyzed for humoral responses toward the streptococcal antigens, especially the M1 and Scl1 proteins. Role of the streptococcal collagen-like protein 1 (Scl1) in anti-PDAC activity was assessed in vivo after intratumoral injection with M1 GAS wild-type, an isogenic mutant strain devoid of Scl1, or a complemented mutant strain with restored scl1 expression. In addition, recombinant Scl1 proteins were tested for NET inhibition using in vitro and ex vivo assays assessing NET production and myeloperoxidase activity.Results: Injection of three different M-type GAS strains reduced subcutaneous pancreatic tumor volume compared to control in two different murine PDAC models. Limitation of tumor growth was dependent on Scl1, as isogenic mutant strain devoid of Scl1 did not reduce tumor size. We further show that Scl1 plays a role in localizing GAS to the tumor site, thereby limiting the systemic spread of bacteria and off-target effects. While mice did elicit a humoral immune response to GAS antigens, tested sera were weakly immunogenic toward Scl1 antigen following intra-tumoral treatment with Scl1-expressing GAS. M1 GAS inhibited NET formation when co-cultured with neutrophils while Scl1-devoid mutant strain did not. Recombinant Scl1 protein inhibited NETs ex vivo in a dose-dependent manner by suppressing myeloperoxidase activity.Discussion: Altogether, we demonstrate that intra-tumoral GAS injections reduce PDAC growth, which is facilitated by Scl1, in part through inhibition of cancer promoting NETs. This work offers a novel strategy by which NETs can be targeted through Scl1 protein and potentiates its use as a cancer therapeutic.
- 7 March 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1363962
Open AccessGroup A streptococcal collagen-like protein 1 restricts tumor growth in murine pancreatic adenocarcinoma and inhibits cancer-promoting neutrophil extracellular traps
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer associated with an immunosuppressive environment. Neutrophil extracellular traps (NETs) were initially described in the context of infection but have more recently been implicated in contributing to the tolerogenic immune response in PDAC. Thus, NETs are an attractive target for new therapeutic strategies. Group A Streptococcus (GAS) has developed defensive strategies to inhibit NETs.Methods: In the present work, we propose utilizing intra-tumoral GAS injection to stimulate anti-tumor activity by inhibiting cancer-promoting NETs. Mice harboring Panc02 or KPC subcutaneous tumors injected with three different M-type GAS strains. Tumors and spleens were harvested at the endpoint of the experiments to assess bacterial colonization and systemic spread, while sera were analyzed for humoral responses toward the streptococcal antigens, especially the M1 and Scl1 proteins. Role of the streptococcal collagen-like protein 1 (Scl1) in anti-PDAC activity was assessed in vivo after intratumoral injection with M1 GAS wild-type, an isogenic mutant strain devoid of Scl1, or a complemented mutant strain with restored scl1 expression. In addition, recombinant Scl1 proteins were tested for NET inhibition using in vitro and ex vivo assays assessing NET production and myeloperoxidase activity.Results: Injection of three different M-type GAS strains reduced subcutaneous pancreatic tumor volume compared to control in two different murine PDAC models. Limitation of tumor growth was dependent on Scl1, as isogenic mutant strain devoid of Scl1 did not reduce tumor size. We further show that Scl1 plays a role in localizing GAS to the tumor site, thereby limiting the systemic spread of bacteria and off-target effects. While mice did elicit a humoral immune response to GAS antigens, tested sera were weakly immunogenic toward Scl1 antigen following intra-tumoral treatment with Scl1-expressing GAS. M1 GAS inhibited NET formation when co-cultured with neutrophils while Scl1-devoid mutant strain did not. Recombinant Scl1 protein inhibited NETs ex vivo in a dose-dependent manner by suppressing myeloperoxidase activity.Discussion: Altogether, we demonstrate that intra-tumoral GAS injections reduce PDAC growth, which is facilitated by Scl1, in part through inhibition of cancer promoting NETs. This work offers a novel strategy by which NETs can be targeted through Scl1 protein and potentiates its use as a cancer therapeutic.